Cited by 36

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Hyaluronic acid/doxorubicin nanoassembly-releasing microspheres for the transarterial chemoembolization of a liver tumor

Lee, Song Yi, Choi, Jin Woo, Lee, Jae-Young, Kim, Dae-Duk, Kim, Hyo-Cheol, Cho, Hyun-Jong·2018·Drug Delivery

DOI 10.1080/10717544.2018.1480673PMC PMC6058484

Open this paper in CoChat — free account

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1080/10717544.2018.1480673

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Figure 1. Scheme of the fabrication process of DOX/HACE MS.CC BY · PubMed Central

Figure 2. Particle characterization of DOX-loaded MS. (A) Size distribution profiles of DOX MS and DOX/HACE MS. (B) CLSM images of DOX MS and DOX/HACE MS. Depth-dependent cross-sectional images were observed by CLSM. Red fluorescence signal in MS indicates the intraparticle distribution of DOX. The length of the scale bar is 5 μm. (C) Particle characteristics of released DOX/HACE nanoassembly from DOX/HACE MS after incubating for 7 days. Size distribution profile (left) and TEM image (right) are presented. The length of the scale bar in the TEM image is 500 nm.CC BY · PubMed Central

Figure 3. In vitro degradation test of fabricated MS. DOX MS (A) and DOX/HACE MS (B) were incubated in PBS (pH 7.4) and FBS for 14 days. The morphology of MS was observed by SEM (scale bar = 20 μm). Inset with the yellow boundary indicates the magnified image (scale bar = 2 μm).CC BY · PubMed Central

Figure 4. Drug release profiles from DOX MS (pH: 7.4) and DOX/HACE MS (pH: 7.4, 6.8, and 5.5). Each point indicates the mean ± SD (n = 3).CC BY · PubMed Central

Figure 5. Cellular accumulation efficiency and in vitro anticancer activities in HepG2 and McA-RH7777 cells. (A) The mean fluorescence intensity values of DOX, measured by flow cytometry, in HepG2 cells and McA-RH7777 cells. Each point indicates the mean ± SD (n = 3). *p < .05, compared with DOX group. #p < .05, compared with DOX MS group. (B) Antiproliferation efficacy, evaluated by MTS-based assay, of DOX-loaded MSs in HepG2 cells and McA-RH7777 cells. Cell viability (%) is presented as the relative percentage based on the control (no treatment) group. Each point indicates the mean ± SD (n = 3). #p < .05, compared with DOX MS group. (C) Apoptotic efficacy of developed MS, measured by Annexin V and PI-based assays, in HepG2 cells and McA-RH7777 cells. UL, LL, LR, and UR indicate upper left, lower left, lower right, and upper right, respectively. Each point indicates the mean ± SD (n = 3). *p < .05, compared with DOX group. #p < .05, compared with DOX MS group.CC BY · PubMed Central

Figure 6. In vivo anticancer activities in the McA-RH7777 tumor-implanted rat model. (A) Serial MR images of liver tumors in control (sham operation), DOX MS, and DOX/HACE MS groups on day 0 (pre-treatment status), 3, and 7 after IA administration. White arrowheads in MR images indicate liver tumor. The length of scale bar in the left side is 1 cm. (B) H&E staining images of dissected liver and tumor, lung, spleen, kidney, and heart in control, DOX MS, and DOX/HACE MS groups. The length of scale bar (shown in the lower right side) in the images of lung, spleen, kidney, and heart is 100 μm.CC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A7RC peptide modified paclitaxel liposomes dually target breast cancer
Cao, J., Wang, R., Gao, N., Li, M., Tian, X., Yang, W., Ruan, Y., Zhou, C., Wang, G., Liu, X., et al. (2015) · Biomaterials Science · doi:10.1039/c5bm00161g · Cited by 93
Redox Sensitive Shell and Core Crosslinked Hyaluronic Acid Nanocarriers for Tumor-Targeted Drug Delivery
Zheng, H., Yin, L., Zhang, X., Zhang, H., Hu, R., Yin, Y., Qiu, T., Xiong, X., & Wang, Q. (2016) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2016.2279 · Cited by 64 · cited 1×
“Among them, hyaluronic acid (HA)-based nanoparticles have been widely investigated as one of the active tumor targeting strategies via CD44 receptor-mediated endocytosis (Zheng et al., 2016a; Hu et al., 2017a).”
Background
Self-Assembled Hyaluronic Acid Nanoparticles for pH-Sensitive Release of Doxorubicin: Synthesis and In Vitro Characterization
Hu, R., Zheng, H., Cao, J., Davoudi, Z., & Wang, Q. (2017) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2017.2406 · Cited by 57 · cited 2×
“To reduce toxicity of nanocarrier itself, biocompatible and biodegradable materials have been introduced to deliver therapeutic cargos (Du et al., 2014; Li et al., 2014; Cao et al., 2015; Wang et al., 2015; Zhang et al., 2016b; Hu et al., 2017b).”
Background

Research works printed but not linked: 39

10.1080/02652040600687613 · DOI
10.1200/JCO.2015.64.0821 · DOI
10.1016/j.jvir.2012.08.025 · DOI
10.1016/j.biomaterials.2011.06.028 · DOI
10.1016/j.biomaterials.2011.10.064 · DOI
10.1371/journal.pone.0115898 · DOI
10.1007/s00261-015-0591-9 · DOI
10.1016/j.colsurfb.2015.05.037 · DOI
10.1038/s41598-017-00709-4 · DOI
10.1016/j.jconrel.2012.01.043 · DOI
10.1016/j.jconrel.2014.03.006 · DOI
10.1016/j.pharmthera.2017.02.010 · DOI
10.3748/wjg.v24.i2.161 · DOI
Gao S, 2013, Hepatogastroenterology, 60, 813
10.1586/era.13.21 · DOI
10.1016/j.suronc.2016.03.002 · DOI
10.1166/jbn.2017.2407 · DOI
10.1016/j.critrevonc.2013.07.003 · DOI
10.1016/j.actbio.2017.02.030 · DOI
10.1016/j.jconrel.2013.10.012 · DOI
10.1007/s11095-012-0839-9 · DOI
10.3350/cmh.2017.0004 · DOI
10.1159/000449347 · DOI
10.1158/0008-5472.CAN-13-2309 · DOI
10.3350/cmh.2017.0111 · DOI
10.1016/j.jconrel.2016.06.021 · DOI
10.1021/acsami.7b06582 · DOI
10.1517/17425247.2011.545388 · DOI
10.1039/c3tb21423k · DOI
10.1021/acsami.7b14330 · DOI
10.1111/j.1742-4658.2011.08071.x · DOI · Paper page
Nishikawa H, 2014, Anticancer Res, 34, 6877
10.1016/j.colsurfb.2014.06.025 · DOI
10.1039/C5TB00617A · DOI
10.1586/14737140.8.10.1623 · DOI
10.1016/S1051-0443(07)61789-8 · DOI
10.1016/j.biomaterials.2012.03.067 · DOI
10.1016/j.addr.2014.12.003 · DOI · Paper page
10.1166/jbn.2016.2278 · DOI

Sorted by citations

Hyaluronic a cid–doxorubicin nanoparticles for targeted treatment of colorectal cancer
Pan, D. C., Krishnan, V., Salinas, A. K., Kim, J., Sun, T., Ravid, S., Peng, K., Wu, D., Nurunnabi, M., Nelson, J. A., et al. (2021) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10166 · Cited by 42

See all 36

Authors: Lee, S. Y., Choi, J. W., Lee, J.-Y., Kim, D.-D., Kim, H.-C., & Cho, H.-J.
Affiliations: College of Pharmacy, Kangwon National University, Chuncheon, Gangwon, Republic of Korea;
Department of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea;
College of Pharmacy, Chungnam National University, Daejeon, Republic of Korea;
College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea
Venue: Drug Delivery
Publisher: Informa UK Limited
Published: 2018-01-01
Volume: 25
Issue: 1
Pages: 1472-1483
ISSN: 1071-7544
1521-0464
DOI: 10.1080/10717544.2018.1480673
PMC: PMC6058484
Cited by: 36
References: 3
Language: en
Licence: creativecommons.org/licenses/by/4.0/ (vor)
Funders: National Research Foundation of Korea (NRF-2017R1E1A1A01074584)
Korea Healthcare technology R&D Project
Ministry of Health & Welfare, Republic of Korea

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Hyaluronic acid/doxorubicin nanoassembly-releasing microspheres for the transarterial chemoembolization of a liver tumor

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Metadata

Record

About these checks